Latest scientific news
The new laboratory will join IRB Barcelona's Aging and Metabolism research programme, expanding the Institute's capabilities in therapeutic discovery.
The team will receive €90,000 to investigate why malignant rhabdoid tumours can resist treatment.
The European grant, worth €2.5M, will allow the recruitment of research personnel and the deployment of advanced tumour analysis technologies.
The project brings together 25 partners across 8 countries and incorporates Almirall, Sanofi, and other pharmaceutical companies to provide feedback and evaluate the practical usefulness of the platform in industrial settings.
Gate2Brain, an IRB Barcelona spin-off, signs a strategic partnership with Shilpa Biocare, including a €7 million investment for a 30.4% equity stake in the company.